186 related articles for article (PubMed ID: 35487679)
1. Correspondence on 'No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related 'physician-reported spondylitis'?'.
Gladman DD; Mease PJ; Bird P; Soriano ER; Chakravarty SD; Shawi M; Lavie F; Gong C; Leibowitz E; Poddubnyy D; Tam LS; Helliwell PS; Kavanaugh A; Deodhar AA; Østergaard M; Baraliakos X
Ann Rheum Dis; 2023 Aug; 82(8):e187. PubMed ID: 35487679
[No Abstract] [Full Text] [Related]
2. Correspondence on 'No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related 'physician-reported spondylitis'?'.
Siebert S; Marzo-Ortega H
Ann Rheum Dis; 2023 Aug; 82(8):e185. PubMed ID: 34844925
[No Abstract] [Full Text] [Related]
3. Response to: Correspondence on 'No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post hoc analyses of psoriatic arthritis-related 'physician-reported spondylitis'?' by Gladman.
Landewé RB; Braun J
Ann Rheum Dis; 2023 Aug; 82(8):e188. PubMed ID: 35487678
[No Abstract] [Full Text] [Related]
4. Response to: Correspondence on 'No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related 'physicianreported spondylitis'?' by Siebert and Marzo-Ortega.
Braun J; Landewé RB
Ann Rheum Dis; 2023 Aug; 82(8):e186. PubMed ID: 34844931
[No Abstract] [Full Text] [Related]
5. No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related 'physician-reported spondylitis'?
Braun J; Landewé RB
Ann Rheum Dis; 2022 Apr; 81(4):466-468. PubMed ID: 34656991
[TBL] [Abstract][Full Text] [Related]
6. IL-23 in axial spondyloarthritis and psoriatic arthritis: a good fit for biological treatment?
Atzeni F; Siragusano C; Masala IF; Antonio C; Valentina P; D'Angelo S
Expert Opin Biol Ther; 2022 Jul; 22(7):843-853. PubMed ID: 35722768
[TBL] [Abstract][Full Text] [Related]
7. Disease characteristics, pathogenesis, and treatment controversies of axial psoriatic arthritis.
Yousif P; Nahra V; Khan MA; Magrey M
Joint Bone Spine; 2024 Jan; 91(1):105625. PubMed ID: 37495073
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial.
Gladman DD; Mease PJ; Bird P; Soriano ER; Chakravarty SD; Shawi M; Xu S; Quinn ST; Gong C; Leibowitz E; Poddubnyy D; Tam LS; Helliwell PS; Kavanaugh A; Deodhar A; Østergaard M; Baraliakos X
Trials; 2022 Sep; 23(1):743. PubMed ID: 36064592
[TBL] [Abstract][Full Text] [Related]
9. Similarities and differences between axial spondyloarthritis and axial psoriatic arthritis.
Wang W; Lee YH; Wei JC; Mease P
Int J Rheum Dis; 2023 Mar; 26(3):407-409. PubMed ID: 36645129
[No Abstract] [Full Text] [Related]
10. Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis.
Schoels MM; Braun J; Dougados M; Emery P; Fitzgerald O; Kavanaugh A; Kvien TK; Landewé R; Luger T; Mease P; Olivieri I; Reveille J; Ritchlin C; Rudwaleit M; Sieper J; Smolen JS; Wit Md; van der Heijde D
Ann Rheum Dis; 2014 Jan; 73(1):238-42. PubMed ID: 23740234
[TBL] [Abstract][Full Text] [Related]
11. Axial spondyloarthritis and psoriatic arthritis: mostly overlapping or substantially different diseases?
Braun J; Coates LC
RMD Open; 2023 May; 9(2):. PubMed ID: 37208031
[No Abstract] [Full Text] [Related]
12. Clearing the fog: A closer look at the differences between axial psoriatic arthritis and axial spondyloarthritis.
Benavent D; Navarro-Compán V
ARP Rheumatol; 2023; 2(1):3-6. PubMed ID: 37042843
[No Abstract] [Full Text] [Related]
13. Pharmacologic treatment of psoriatic arthritis and axial spondyloarthritis with traditional biologic and non-biologic DMARDs.
Soriano ER; Acosta-Felquer ML; Luong P; Caplan L
Best Pract Res Clin Rheumatol; 2014 Oct; 28(5):793-806. PubMed ID: 25488785
[TBL] [Abstract][Full Text] [Related]
14. JAK inhibitors, psoriatic arthritis, and axial spondyloarthritis: a critical review of clinical trials.
Keeling S; Maksymowych WP
Expert Rev Clin Immunol; 2021 Jul; 17(7):701-715. PubMed ID: 33944642
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy for pain management in inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis).
Ramiro S; Radner H; van der Heijde D; van Tubergen A; Buchbinder R; Aletaha D; Landewé RB
Cochrane Database Syst Rev; 2011 Oct; (10):CD008886. PubMed ID: 21975788
[TBL] [Abstract][Full Text] [Related]
16. An overview of biologic disease-modifying antirheumatic drugs in axial spondyloarthritis and psoriatic arthritis.
So A; Inman RD
Best Pract Res Clin Rheumatol; 2018 Jun; 32(3):453-471. PubMed ID: 31171315
[TBL] [Abstract][Full Text] [Related]
17. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force.
Smolen JS; Braun J; Dougados M; Emery P; Fitzgerald O; Helliwell P; Kavanaugh A; Kvien TK; Landewé R; Luger T; Mease P; Olivieri I; Reveille J; Ritchlin C; Rudwaleit M; Schoels M; Sieper J; Wit Md; Baraliakos X; Betteridge N; Burgos-Vargas R; Collantes-Estevez E; Deodhar A; Elewaut D; Gossec L; Jongkees M; Maccarone M; Redlich K; van den Bosch F; Wei JC; Winthrop K; van der Heijde D
Ann Rheum Dis; 2014 Jan; 73(1):6-16. PubMed ID: 23749611
[TBL] [Abstract][Full Text] [Related]
18. Risk of infections in psoriatic arthritis or axial spondyloarthritis patients treated with targeted therapies: A meta-analysis of randomized controlled trials.
Séauve M; Auréal M; Laplane S; Lega JC; Cabrera N; Coury F
Joint Bone Spine; 2024 May; 91(3):105673. PubMed ID: 38042364
[TBL] [Abstract][Full Text] [Related]
19. Correspondence on "Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial" by Molto
Kiltz U; Braun J
Ann Rheum Dis; 2023 Dec; 82(12):e229. PubMed ID: 34725049
[No Abstract] [Full Text] [Related]
20. Suspecting and Diagnosing the Patient with Spondyloarthritis and What to Expect from Therapy.
Mease PJ
Rheum Dis Clin North Am; 2022 May; 48(2):507-521. PubMed ID: 35400375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
